This formulation combines CJC-1295, a synthetic growth hormone–releasing hormone (GHRH) analogue, with Ipamorelin, a selective growth hormone secretagogue (GHS). Together, these peptides have been investigated in preclinical models for their potential complementary effects on growth hormone pathways.
Key Research Characteristics:
-
CJC-1295 – Studied for its ability to bind to and activate GHRH receptors, potentially influencing growth hormone secretion in research models.
-
Ipamorelin – Investigated for its selective stimulation of the ghrelin receptor, triggering growth hormone release without significantly affecting cortisol or prolactin in studies.
-
Combination approach explored for sustained and synergistic growth hormone pathway activation in laboratory settings.
-
High-purity, research-grade formulation.
Intended Use:
For qualified research professionals only. All products are intended for laboratory research purposes and are not approved for human use. Not for human consumption, therapeutic, or diagnostic applications.
Disclaimer
Products are furnished for LABORATORY RESEARCH USE ONLY. This product should only be handled by qualified, and licensed professionals. The product may not be used as a drug, agricultural or pesticidal product, food additive or household chemical – and may not be misbranded as such. All information on this website is available for educational purposes only. Bodily introduction of any kind into humans and/or animals is strictly forbidden by law.
Reviews
There are no reviews yet.